Drug General Information |
Drug ID |
D0Z3XC
|
Former ID |
DNC007290
|
Drug Name |
N-(2,6-diphenylpyrimidin-4-yl)acetamide
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H15N3O
|
Canonical SMILES |
CC(=O)NC1=NC(=NC(=C1)C2=CC=CC=C2)C3=CC=CC=C3
|
InChI |
1S/C18H15N3O/c1-13(22)19-17-12-16(14-8-4-2-5-9-14)20-18(21-17)15-10-6-3-7-11-15/h2-12H,1H3,(H,19,20,21,22)
|
InChIKey |
ZFBASLSZDCISGS-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
Adenosine A1 receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A2a receptor |
Target Info |
Inhibitor |
[1]
|
Adenosine A3 receptor |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
cAMP signaling pathway
|
Sphingolipid signaling pathway
|
Neuroactive ligand-receptor interaction
|
Morphine addictionhsa04015:Rap1 signaling pathway
|
Calcium signaling pathway
|
Vascular smooth muscle contraction
|
Parkinson's disease
|
Alcoholism
|
NetPath Pathway
|
TCR Signaling Pathway
|
RANKL Signaling Pathway
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
Pathway Interaction Database
|
HIF-2-alpha transcription factor network
|
PathWhiz Pathway
|
Intracellular Signalling Through Adenosine Receptor A2a and Adenosine
|
Reactome
|
Adenosine P1 receptors
|
G alpha (i) signalling eventsR-HSA-187024:NGF-independant TRKA activation
|
G alpha (s) signalling events
|
Surfactant metabolismR-HSA-417973:Adenosine P1 receptors
|
G alpha (i) signalling events
|
WikiPathways
|
Nucleotide GPCRs
|
GPCRs, Class A Rhodopsin-like
|
GPCR ligand binding
|
GPCR downstream signalingWP80:Nucleotide GPCRs
|
Monoamine Transport
|
NGF signalling via TRKA from the plasma membrane
|
GPCR downstream signaling
|
GPCRs, OtherWP80:Nucleotide GPCRs
|
GPCRs, Other
|
References |
REF 1 | J Med Chem. 2004 Dec 16;47(26):6529-40.2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. |